Cephalexin Dosing for Soft Tissue Toe Infection
For an adult with an uncomplicated soft tissue toe infection, normal renal function, and no β-lactam allergy, prescribe cephalexin 500 mg orally four times daily for 7 days. This is the standard dosing recommended by both IDSA guidelines and FDA labeling for skin and soft tissue infections 1, 2.
Dosing Rationale
The IDSA guidelines explicitly list cephalexin 500 mg four times daily (QID) as appropriate treatment for methicillin-susceptible Staphylococcus aureus (MSSA) skin and soft tissue infections 1. The FDA label confirms this dosing for skin and skin structure infections, noting that 500 mg every 12 hours may be used for uncomplicated cases, but the QID regimen remains standard 2.
Key Evidence Supporting This Approach:
Clinical effectiveness: A 2018 non-inferiority trial demonstrated that cephalexin 500 mg QID achieved 95.8% treatment success at 72 hours for uncomplicated mild-moderate SSTIs, with 100% clinical cure at 7 days 3
Duration: 7 days is the standard treatment duration for uncomplicated soft tissue infections 2, 3
Pathogen coverage: Cephalexin provides excellent coverage for the typical pathogens in non-purulent cellulitis—primarily β-hemolytic streptococci and MSSA 1
Important Clinical Considerations
When Cephalexin May NOT Be Appropriate:
Purulent infections or abscesses: If there is purulent drainage, consider MRSA coverage instead. The IDSA guidelines recommend incision and drainage as primary treatment for abscesses, with antibiotics potentially unnecessary after adequate drainage 1, 4
MRSA risk factors: If the patient has failed initial antibiotic treatment, has systemic inflammatory response syndrome (SIRS), or other MRSA risk factors, choose an agent with MRSA activity such as trimethoprim-sulfamethoxazole or doxycycline 1
Severe infection: For patients with SIRS criteria (fever >38°C or <36°C, tachycardia >90 bpm, tachypnea >24 breaths/min, WBC >12,000 or <4,000), consider parenteral therapy 1
Dosing Alternatives:
While 500 mg QID is standard, emerging evidence suggests 500 mg twice daily may be equally effective for uncomplicated infections. A 2023 pilot trial showed high-dose cephalexin (1000 mg QID) had lower treatment failure rates (3.2%) compared to standard dosing (12.9%), though with more minor adverse effects 5. However, this remains investigational and the standard 500 mg QID dosing should be used in routine practice.
Common Pitfalls to Avoid:
Don't add MRSA coverage empirically: A 2017 trial showed that adding trimethoprim-sulfamethoxazole to cephalexin for non-purulent cellulitis provided no benefit over cephalexin alone 6
Don't prescribe antibiotics for simple abscesses: If the toe infection is a simple abscess without surrounding cellulitis, incision and drainage alone may be sufficient—one study showed 90.5% cure with drainage alone, even with MRSA 4
Ensure adequate drainage first: For any purulent collection, drainage is the primary treatment; antibiotics are adjunctive
Administration Details:
- Take with or without food (though food may reduce GI upset)
- Emphasize completing the full 7-day course
- Refrigerate suspension formulations if used 2
- Follow up in 48-72 hours to assess response